A recent study suggested that 12/15-lipoxygenase (12/15-LOX) inhibition counteracts diabetes related MAPK phosphorylation in mouse and cell culture models of diabetic neuropathy and implies that 12/15-LOX inhibitors may be an effective treatment for DPN [18]. This evidence concerns the gene LOX and diabetic neuropathy.